These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 16626166)

  • 1. Efficacy of alemtuzumab in organ transplantation: current clinical status.
    Ciancio G; Burke GW; Warque ME; Miller J
    BioDrugs; 2006; 20(2):85-92. PubMed ID: 16626166
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alemtuzumab (Campath-1H): a systematic review in organ transplantation.
    Morris PJ; Russell NK
    Transplantation; 2006 May; 81(10):1361-7. PubMed ID: 16732169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alemtuzumab in solid organ transplantation and in composite tissue allotransplantation.
    Weissenbacher A; Boesmueller C; Brandacher G; Oellinger R; Pratschke J; Schneeberger S
    Immunotherapy; 2010 Nov; 2(6):783-90. PubMed ID: 21091110
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The evolving role of alemtuzumab (Campath-1H) for immunosuppressive therapy in organ transplantation.
    Magliocca JF; Knechtle SJ
    Transpl Int; 2006 Sep; 19(9):705-14. PubMed ID: 16918530
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Some observations on prope tolerance.
    Calne R; Watson CJ
    Curr Opin Organ Transplant; 2011 Aug; 16(4):353-8. PubMed ID: 21666472
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging role of Alemtuzumab in renal and renal-pancreas transplantation.
    Sureshkumar KK; Hussain SM; Zimmer BW; Marcus RJ
    Expert Opin Biol Ther; 2008 Oct; 8(10):1605-25. PubMed ID: 18774927
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alemtuzumab induction in deceased donor kidney transplantation.
    Shin M; Song SH; Kim JM; Kwon CH; Joh JW; Lee SK; Kim SJ
    Transplant Proc; 2011; 43(6):2365-78. PubMed ID: 21839271
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of alemtuzumab in facilitating maintenance immunosuppression minimization following solid organ transplantation.
    Agarwal A; Shen LY; Kirk AD
    Transpl Immunol; 2008 Nov; 20(1-2):6-11. PubMed ID: 18824230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alemtuzumab (Campath-1H) for treatment of lymphoid malignancies in the age of nonmyeloablative conditioning?
    Hale G; Slavin S; Goldman JM; Mackinnon S; Giralt S; Waldmann H
    Bone Marrow Transplant; 2002 Dec; 30(12):797-804. PubMed ID: 12476271
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alemtuzumab (Campath-1H) induction therapy and dendritic cells: Impact on peripheral dendritic cell repertoire in renal allograft recipients.
    Kirsch BM; Haidinger M; Zeyda M; Böhmig GA; Tombinsky J; Mühlbacher F; Watschinger B; Hörl WH; Säemann MD
    Transpl Immunol; 2006 Nov; 16(3-4):254-7. PubMed ID: 17138063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alemtuzumab (Campath-1H) in kidney transplantation.
    Ciancio G; Burke GW
    Am J Transplant; 2008 Jan; 8(1):15-20. PubMed ID: 18093269
    [TBL] [Abstract][Full Text] [Related]  

  • 12. T-cell depleting antibodies: new hope for induction of allograft tolerance in bone marrow transplantation?
    Simpson D
    BioDrugs; 2003; 17(3):147-54. PubMed ID: 12749751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H).
    Kirk AD; Hale DA; Mannon RB; Kleiner DE; Hoffmann SC; Kampen RL; Cendales LK; Tadaki DK; Harlan DM; Swanson SJ
    Transplantation; 2003 Jul; 76(1):120-9. PubMed ID: 12865797
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alemtuzumab (Campath 1H) induction with tacrolimus monotherapy is safe for high immunological risk renal transplantation.
    Thomas PG; Woodside KJ; Lappin JA; Vaidya S; Rajaraman S; Gugliuzza KK
    Transplantation; 2007 Jun; 83(11):1509-12. PubMed ID: 17565326
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CAMPATH-1 antibodies in stem-cell transplantation.
    Hale G; Cobbold S; Novitzky N; Bunjes D; Willemze R; Prentice HG; Milligan D; MacKinnon S; Waldmann H;
    Cytotherapy; 2001; 3(3):145-64. PubMed ID: 12171722
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Present experience with Campath-1H in organ transplantation and its potential use in pediatric recipients.
    Knechtle SJ
    Pediatr Transplant; 2004 Apr; 8(2):106-12. PubMed ID: 15049789
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alemtuzumab (Millennium/ILEX).
    Dumont FJ
    Curr Opin Investig Drugs; 2001 Jan; 2(1):139-60. PubMed ID: 11527007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells.
    Hale G; Jacobs P; Wood L; Fibbe WE; Barge R; Novitzky N; Toit C; Abrahams L; Thomas V; Bunjes D; Duncker C; Wiesneth M; Selleslag D; Hidajat M; Starobinski M; Bird P; Waldmann H
    Bone Marrow Transplant; 2000 Jul; 26(1):69-76. PubMed ID: 10918407
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alemtuzumab induction in renal transplantation.
    Hanaway MJ; Woodle ES; Mulgaonkar S; Peddi VR; Kaufman DB; First MR; Croy R; Holman J;
    N Engl J Med; 2011 May; 364(20):1909-19. PubMed ID: 21591943
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Monoclonal antibodies in renal transplantation].
    Bonvoisin C; Weekers L; Grosch S; Krzesinski JM
    Rev Med Liege; 2009; 64(5-6):287-92. PubMed ID: 19642461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.